Study summary · research use only
Methylene blue treatment in experimental ischemic stroke: a mini review
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This mini review discusses methylene blue, a drug with a long history of use in humans for treating methemoglobinemia and cyanide poisoning, in the context of studies on experimental stroke models (species not specified). The abstract states methylene blue has recently been shown to have neuroprotective effects in neurodegenerative disease and brain injury models, and that the goal of the paper is to review studies of methylene blue in experimental stroke models.
Abstract
Stroke is a leading cause of death and long-term disability. Methylene blue, a drug grandfathered by the Food and Drug Administration with a long history of safe usage in humans for treating methemoglobinemia and cyanide poisoning, has recently been shown to be neuroprotective in neurodegenerative diseases and brain injuries. The goal of this paper is to review studies on methylene blue in experimental stroke models.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.